Full Press Release Details
INC. ANNOUNCES $6.5 MILLION REGISTERED DIRECT OFFERING
FL, (December 24, 2020) - Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"),
a company focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic, today announced
it has entered into definitive agreements with investors for the purchase and sale of 14,444,444 shares of its common stock at
a purchase price of $0.45 per share in a registered direct offering. The closing of the offering is expected to occur on or about
December 29, 2020, subject to the satisfaction of customary closing conditions.
Global Partners is acting as sole placement agent for the offering.
offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333- 235763) previously filed
with the U.S. Securities and Exchange Commission (the "SEC"). A prospectus supplement describing the terms of the
proposed offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Electronic
copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue,
28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com. Before investing in
this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and
the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and
the accompanying prospectus, which provide more information about the Company and such offering.
press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these
securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or jurisdiction.
Inc. is focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic and the further
development of effective treatments for novel antibiotics against infectious disease. The Company is dedicated to the development
and commercialization of a vaccine candidate providing specific immunity from novel coronavirus. The Terra CoV-2 immunization
leverages coronavirus spike protein research conducted by the National Institute of Health. In addition, Oragenics has an exclusive
worldwide channel collaboration with ILH Holdings, Inc. (n/k/a Eleszto Genetika, Inc.), relating to the development of novel lantibiotics.
press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of
1995, as amended, that involve significant risks and uncertainties about Oragenics, including but not limited to statements with
respect to the completion, timing, size, and use of proceeds of the proposed underwritten offering of common stock. Oragenics
may use words such as "expect," "anticipate," "project," "intend," "plan,"
"aim," "believe," "seek," "estimate," "can," "focus,"
"will," and "may" and similar expressions to identify such forward-looking statements. Among the important
factors that could cause actual results to differ materially from those indicated by such forward-looking statements are risks
relating to, among other things, whether or not Oragenics will be able to raise capital, the final terms of the registered direct
offering of common stock, market and other conditions, the satisfaction of customary closing conditions related to the registered
direct offering of common stock, Oragenics' business and financial condition, and the impact of general economic, industry
or political conditions in the United States or internationally. For additional disclosure regarding these and other risks faced
by Oragenics, see disclosures contained in Oragenics' public filings with the SEC, including the "Risk Factors"
in the company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and prospectus for this offering. You should
consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance
on such statements. The forward-looking statements are made as of the date hereof, and Oragenics undertakes no obligation to update
such statements as a result of new information, except as required by law.
Sullivan, 813-286-7900
julesa@coreir.com Investors: